Yonsei Med J.  2017 May;58(3):533-539. 10.3349/ymj.2017.58.3.533.

Perceptions of Postmenopausal Symptoms and Treatment Options among Middle-Aged Korean Women

• Kim MK
• Seo SK
• Chae HD
• Hwang KJ
• Kim T
• Yoon BK
• Lee BS

• KMID: 2419110
• DOI: http://doi.org/10.3349/ymj.2017.58.3.533

Abstract

PURPOSE
To investigate the perceptions of postmenopausal symptoms and treatment options among middle-aged Korean women.
MATERIALS AND METHODS
This cross-sectional study included 2330 Korean women. The women were administered a structured questionnaire to collect sociodemographic data and information regarding menopause and its treatment.
RESULTS
More than half (65%) of the participants perceived menopause as a disease, and 66.8% knew hormone therapy (HT) is available for menopausal symptom treatment. However, only 19.7% of participants visited clinics for HT. The most common reasons for having negative views about HT were its adverse reactions (47.3%) and concerns about developing cancer (41.1%). For symptom management, 36.5% of the participants tried lifestyle modification instead of HT.
CONCLUSION
The majority of Korean women regarded menopause as a disease. They were aware of HT for menopausal symptom treatment, but the use of HT was relatively low. Education about the safety and positive effects of HT and the importance of professional healthcare should be provided.

Keyword

Postmenopause; hormone replacement therapy; middle aged

MeSH Terms

Aged
Cross-Sectional Studies
Estrogen Replacement Therapy/adverse effects/*psychology
Female
*Health Knowledge, Attitudes, Practice
Humans
Menopause/*psychology
Middle Aged
Postmenopause/*ethnology
Republic of Korea
Surveys and Questionnaires
*Women's Health

Figure

• 

  Fig. 1 Sociodemographic data of the study population.

Reference

1. Cheng MH, Wang SJ, Wang PH, Fuh JL. Attitudes toward menopause among middle-aged women: a community survey in an island of Taiwan. Maturitas. 2005; 52:348–355.

2. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006; 96:1226–1235.

3. Panay N, Hamoda H, Arya R, Savvas M. British Menopause Society and Women's Health Concern. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19:59–68.

4. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004; (4):CD002978.

5. Burger HG, MacLennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women’s health. Climacteric. 2012; 15:281–287.

6. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22:1155–1172.

7. Depypere H, Pintiaux A, Desreux J, Hendrickx M, Neven P, Marchowicz E, et al. Coping with menopausal symptoms: an internet survey of Belgian postmenopausal women. Maturitas. 2016; 90:24–30.

8. Jin F, Tao M, Teng Y, Shao H, Li C, Mills E. Knowledge and attitude towards menopause and hormone replacement therapy in Chinese women. Gynecol Obstet Invest. 2015; 79:40–45.

9. Tserotas K, Hernandez L, Morera F, Pineda R, Chedraui P. Treatment for the menopause in Central America: use, knowledge, perceptions and attitudes among urban living middle-aged women. Gynecol Endocrinol. 2011; 27:504–511.

10. Choi H, Lee HK, Park HM. The Korean menopausal women’s attitudes and awareness on menopause: results of Korean Gallup epidemiologic survey on menopause and HRT. J Korean Soc Menopause. 2003; 9:36–43.

11. Park HM, Choi H, Lee HK. The HRT awareness and acceptance in Korean postmenopausal women: results of Korean Gallup epidemiologic survey on menopause and HRT. J Korean Soc Menopause. 2002; 8:3–18.

12. Chae HD, Choi SY, Cho EJ, Cho YM, Lee SR, Lee ES, et al. Awareness and experience of menopausal symptom and hormone therapy in Korean postmenopausal women. J Menopausal Med. 2014; 20:7–13.

13. Memon FR, Jonker L, Qazi RA. Knowledge, attitudes and perceptions towards menopause among highly educated Asian women in their midlife. Post Reprod Health. 2014; 20:138–142.

14. Yum SK, Kim T. Gaps in menopause knowledge. J Menopausal Med. 2014; 20:47–51.

15. Kyvernitakis I, Kostev K, Hars O, Albert US, Hadji P. Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era. Climacteric. 2015; 18:737–742.

16. Kim JY, Sang JH, Park HM. The change of hormone therapy in postmenopausal women in Korea before and after women’s health initiative study: 2000~2009. Korean J Obstet Gynecol. 2010; 53:1110–1117.

17. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.

18. de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016; 91:153–155.

19. Aedo S, Cavada G, Blümel JE, Chedraui P, Fica J, Barriga P, et al. Women’s Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks. Menopause. 2015; 22:1317–1322.

20. Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric. 2012; 15:241–249.

21. Song Y, Santen RJ, Wang JP, Yue W. Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro. Endocrinology. 2013; 154:656–665.

22. Song Y, Santen RJ, Wang JP, Yue W. Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology. 2012; 153:5706–5715.